New diagnostic and therapeutic tools
against multidrug resistant tumours

We aim to improve both
the diagnosis and therapy
of multidrug resistant (MDR)
solid tumours.

Welcome!

STRATAGEM contributes to Covid-19 research

Fighting together
against multidrug
resistant tumours

Special
issues
edited by
our scientists

Working
Group 1

Identification of new biomarkers and therapeutic targets for MDR tumours

Working
Group 2

Synthesis and nanodelivery strategies for new therapeutic tools against MDR tumours

Working
Group 3

Efficacy validation of new therapeutic tools against pre-clinical models of MDR tumours

Working
Group 4

Pharmacokinetics and ADMET of the new therapeutic tools; safety of the targets

Forum

Events / News